GFAP and Alexander disease: In some studies, astrocytes have been the viable therapeutic target in pathologies of the nervous system (Liu et al., 2015; Smethurst et al., 2020), and it has been demonstrated that CRYAB has the ability to dissolve toxic protein aggregates such as amyloid beta in Alzheimer’s disease, alpha synuclein in the Parkinson’s disease, and GFAP in Alexander’s disease (Rekas et al., 2004; Narayanan et al., 2006; Hagemann et al., 2009; Tang et al., 2010; Cox et al., 2014).